Fund holdings
1.7MShares reported · +972K vs prior quarter
From a 13F filed Aug 14, 2026 covering holdings at Jun 30, 2026 — a quarter-end snapshot, not a live trade.
Loading…
VTRS · NASDAQ · Pharmaceuticals
Pharmaceuticals company based in Pittsburgh, Pennsylvania.
Last close, Oct 1, 2026
$17.46
Adjusted for splits and dividends
Last 12 months
+73.0%
S&P 500 +14.3% over the same dates
Market value
$20.1B
Last close × shares outstanding
Bets against the stock: 40.8M shares sold short (3.6% of shares outstanding), +5.6% vs the previous count, 5.6 days of normal trading to buy them back. FINRA, as of Sep 15, 2026.
Insiders buying, last 90 days
None
No open-market purchases reported
Insiders selling, last 90 days
None
No open-market sales reported
New federal contracts, 12 months
None
Nothing found for this company
Revenue, fiscal 2025
$14.3B
-3.0% vs the year before
Net income
Not reported
As reported in the annual filing
Shares outstanding
1.15B
As of Aug 3, 2026
In fiscal 2025 the company spent $501M buying back its own shares. Cash actually paid, from its cash-flow statement.
From a 13F filed Aug 14, 2026 covering holdings at Jun 30, 2026 — a quarter-end snapshot, not a live trade.
A Schedule 13G is filed by holders above 5% who say they will not try to influence the company. Index funds and large asset managers file most of them.
Officer sold ~$810K of Viatris
Scheduled in advanceStock since the trade +31.4% · S&P 500 +16.6% · to Oct 1
Viatris's See Remarks sold $284K of Viatris shares. Nobody planned it ahead of time.
Stock since the trade +67.6% · S&P 500 +18.1% · to Oct 1
A board member of Viatris spent $3K of their very own money to buy Viatris shares. Their pile of Viatris shares grew by 42%.
Prices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
11 approvals or clearances and 6 recalls recorded by the FDA for this company and its listed subsidiaries.
From openFDA: Drugs@FDA (new applications and new uses), device 510(k) and PMA decisions, and FDA enforcement reports. Class I recalls are the most serious, Class III the least. Most recalls are started by the company itself. Labeling and manufacturing changes are not listed.
Federal rules, proposed rules and notices that name the company by its legal name, from the Federal Register. Being named is not the same as being the target of a rule.
FMR LLC
Schedule 13G: passive · filed Sep 8, 2026 · 127M shares
Vanguard Capital Management
Schedule 13G: passive · filed Apr 30, 2026 · 84.8M shares
BlackRock, Inc.
Schedule 13G: passive · filed Oct 17, 2025 · 76.4M shares
DAVIS SELECTED ADVISERS
Schedule 13G: passive · filed Aug 12, 2026 · 75.2M shares
Anyone owning more than 5% must file within days. Structured filings exist since December 2024, so older stakes that were never amended may be missing.
Last 12 months, adjusted daily closes
Adjusted close went from $10.09 on Oct 1, 2025 to $17.46 on Oct 1, 2026 (+73.0%). Disclosed trades in the last 12 months: 1 insider purchase, 2 insider sales (1 under pre-arranged plans), 1 Congress purchase, 0 Congress sales.
Short sale volume: 42.4% of the volume reported to FINRA over the last 20 trading days was marked short, below its 1-year average of 45.7%. FINRA daily files, to Oct 2, 2026.
Fails to deliver: 158K shares (about $2.61M) were not delivered on time for settlement on Sep 14, 2026. SEC fails-to-deliver data.
Short sale volume is not short interest. It counts trades marked short, including market makers selling short to fill buy orders, so it is a share of daily trading, not a count of bets against the stock. Fails to deliver have many causes, including processing delays, and are often resolved within days.